Author:
Raghunath Arrvind,Desai Kunal,Ahluwalia Manmeet S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference95 articles.
1. Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J. & Steeg, P. S. CNS Metastases in breast cancer: old challenge, new frontiers CME Staff Planners’ disclosures acknowledgment of financial or other support. Clin Cancer Res 19, (2013).
2. Smid M, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–14.
3. Venur VA, Ahluwalia MS. Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015;4:18.
4. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG Database. Int J Radiat Oncol. 2008;70:510–4.
5. • Sperduto PW, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82:2111–7 The authors further refined the Breast Graded Prognostic Assessment (GPA) by using multivariate Cox regression (MCR) and recursive partitioning analysis (RPA) on a multi-institutional, retrospective cohort of N = 400 breast cancer patients with newly diagnosed brain metastases to identify prognostic factors related to survival. In doing so, they identified the following: Karnofsky Performance Status (KPS) and tumor subtypes (namely HER2, ER/PR status and the interaction between these two).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献